By Ryan Davis ( April 23, 2014, 8:25 PM EDT) -- Myriad Genetics Inc. on Friday asked the Federal Circuit to revive its bid for an injunction on Ambry Genetics Corp.'s cancer-testing products, arguing the lower court judge incorrectly held that Myriad's patents were likely invalid for claiming patent-ineligible subject matter....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.